Optimizing And Scaling Lentiviral Vector Production

Achieving Industry-Leading Titers With The VirusExpress® Platform

The VirusExpress® platform for lentiviral (LV) vectors is a defined and de-risked approach for production that leverages almost three decades of experience in viral vector development and manufacture and fit-for-purpose products to produce industry-leading titers while meeting industry expectations for recovery yield. Here, we outline how the platform's upstream and downstream workflows have been optimized through the use of design of experiments (DoE) and supplementary studies. These optimization studies help establish the VirusExpress® LV platform as a scalable, robust, and streamlined solution for suspension-based LV vector manufacturing as it addresses the needs of cell and gene therapy innovators.